A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Kissei

Status and phase: Completed; Phase 2

Conditions: Dry Eye Syndromes

Treatments: Drug: KCT-0809 ophthalmic solution; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01890941

KCT1205

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Corneal and conjunctival damage
• Insufficiency of lacrimal secretion
• Ocular symptom

Exclusion criteria

• Severe ophthalmic disorder
• Punctual plugs or surgery for occlusion of the lacrimal puncta

Trial design

0 participants in 3 patient groups, including a placebo group

KCT-0809 Lower Dose

Experimental group

Treatment:

Drug: KCT-0809 ophthalmic solution

KCT-0809 Higher Dose

Experimental group

Treatment:

Drug: KCT-0809 ophthalmic solution

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo